Summary
The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Colombia, Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Colombia 2020 Forum is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Colombia and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speakers
Gloria Berrutti
Neolpharma, Mexico
Director of International Business Latam
Patrick Devlyn
Business Coordinating Council of Mexico, Mexico
President Healthcare Commission
José Avalos Rogel
Nouvelle Pharmaceutiques, Mexico
General Director
Latam Biosimilars’s Insight. Panel Industry Leaders
Edgar Mauricio Rubio
Indukern, Colombia
Pharmaceutical & Animal Health Division Manager
Eduardo Cioppi
mAbxience, Argentina
Regional Director – Latin America
Jaime Uribe
PROBIOMED, Mexico
CEO